
Honored to speak at #ASH2025 in Orlando as part of the ASH Education Program. Great session on Rare B-Cell Malignancies in 2025 #Hematology #BCellMalignancies #Lymphoma #Leukemia #MedicalEducation #Oncology #ClinicalResearch

Hematologist, Transplant Physician. | Opinions expressed are my own and not in any official or professional capacity. UPMC Hillman Cancer Center, Harrisburg

Honored to speak at #ASH2025 in Orlando as part of the ASH Education Program. Great session on Rare B-Cell Malignancies in 2025 #Hematology #BCellMalignancies #Lymphoma #Leukemia #MedicalEducation #Oncology #ClinicalResearch

Congratulations to Dr. Faith Seltun, DO for Selecting the Emerging Leaders Program - Salman Fazal (@salmanf) oncodaily.com/voices/salman-…

What Makes the Oncology Community in Pittsburgh So Strong? - Salman Fazal M.D (@salmanf) oncodaily.com/voices/salman-…



New 2026 #ASTCT consensus grading adds IEC-associated enterocolitis (IEC-EC) after BCMA CAR-T, most often cilta-cel: • Delayed onset: weeks to months • Non-bloody grade ≥3 diarrhea • Often steroid-refractory • Grade by CTCAE, not clonality #CARTcell #mmsm @UPMCHeme_Onc @MM_Hub

🧬 The PRISM Risk Model for AML (HMA + Venetoclax) ELN describes the leukemia. PRISM estimates how it behaves on azacitidine/decitabine + venetoclax. 17 variables across 3 domains → one continuous score → 3 risk groups: 🟢 Low ≈ 26 mo 🟡 Intermediate ≈ 14 mo 🔴 High ≈ 6 mo Reclassifies ~40% of patients vs ELN; >50% of ELN-“favorable” move categories. Better discrimination than the 4-gene model (C-index 0.72 vs 0.61). Free calculator → prism-aml.com Kadia et al. J Clin Oncol. 2026;44(19):2030–2038. #AML #LeukSM #HemeOnc #MedEd

MRD in myeloma is entering its 3rd era: prognosis → trial endpoint → guiding treatment. Gonzalez et al, @BloodJournal: 5 serial MRD trajectories outperform R-ISS. In a mouse model, BCMA CAR T given during persistent MRD beat the same therapy at relapse. #mmsm #MRD @UPMCHeme_Onc @MM_Hub

💡 AML pearl: a standard NGS panel can miss FLT3‑ITD, especially large ones. Fragment analysis remains the standard. Know your lab’s assay, because ELN risk and FLT3 inhibitor eligibility depend on it. #AML #LeukSM #MedEd #hemonc #MedTwitter: #OncTwitter: #leusm @UPMCHeme_Onc

Some evenings remind you why you love this field. Last night in Pittsburgh was one of them. 💙 Thank you to everyone who filled the room at Cancer Updates From Major Oncology Meetings – Pittsburgh. It was an honor to co-chair this program with Dr. Adam brufsky and to share the latest in hematologic malignancies. The science was excellent, but I'll remember the energy in the room most. Oncologists, APPs, nurses, pharmacists, and fellows came together after a full day at work. The questions were thoughtful, the hallway conversations ran long, and colleagues who hadn't seen each other met up. Coming back to Pittsburgh always feels like coming home. So many of the people in that room worked with me, referred patients to me, or cared for patients alongside me over the years. The oncology community here is one of the strongest anywhere. Meetings like this matter. A trial result becomes better care only when colleagues talk it through together, compare notes, and take it back to their patients. Thank you to Total Health, our faculty, Dr. Elshad Hasanov, Dulabh Kaur Monga, Christopher Lemmon, and everyone who joined us! @UPMCHillmanCC @TotalHealthConf @CyrusKhann @HasanovLab #hemonc @oncodaily @AJMC_Journal @BloodCancerUtd @aamdsif #MedTwitter: #OncTwitter: #mmsm #lymsm , #leusm #MPNsm

👉👉👉Proud to have co-led our debut special session:: 2026 Emerging Leaders Program (ELP) Roundtable at the 18th Intl MPN Congress w/ J Mascarenhas & @DrJoeScandura ! Delighted that we were able to highlight our early career investigators-future of our MPN field !! #MPNSM

Proud of Dr. Faith Seltun 👏 Selected for the #MPN Congress Emerging Leaders Program & presented our study of SGLT2i in PV. Huge thanks to Dr. @Wajeheme , Dr. @ashar_ali and Zainab Mohyuddin @UPMCHillmanCC @RoswellPark @MPN_RF @MPN_Hub @AHNhemeonc @VoicesofMPN #mpnsm #mpncongress #mpncongress2026

New publication 📝 Results from the phase III DALIAH trial, published in eClinicalMedicine, show pegylated interferon alpha-2 achieves superior long-term JAK2 V617F molecular responses vs hydroxyurea in patients with MPN who remained on long-term therapy (67% vs 35% at 60 months; p = 0.03). Learn more about MPN: bit.ly/4acXNKD #MPN #MPNsm #MedNews #MedEd

New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification onlinelibrary.wiley.com/doi/… #mpnsm

Living with an MPN? Let's talk about symptoms. 🩸 Fatigue, itching, night sweats, an enlarged spleen, bone pain. For many people with polycythemia vera, essential thrombocythemia, or myelofibrosis, symptoms affect daily life as much as blood counts do. On Monday, November 2 at 12:00 PM ET, I'll be joining HealthTree Foundation for a free online webinar: Understanding Your MPN Symptoms. We'll leave plenty of time for live Q&A, so bring your questions. Can't make it live? Register anyway, and HealthTree will email you the recording. Please share with anyone in your life affected by an MPN. 💙 #MPNsm #Myelofibrosissm #PolycythemiaVera #EssentialThrombocythemia @BloodCancerUtd @MPN_RF @HealthTree @UPMCHillmanCC 👉 Register: healthtree.org/events/nov26-…

Early in my career, I learned that not all heroes work in front of the patient. Some work behind the scenes: on rounds, writing safe protocols, adjusting premeds, and making busulfan PK possible. Thank you, clinical pharmacists. As #PharmacyWeek wraps up, we see you. 💊 @UPMCHillmanCC @UPMC